Myxoid Liposarcoma Overview

Save information for later
Sign Up

Learn About Myxoid Liposarcoma

What is the definition of Myxoid Liposarcoma?
Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body's fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and Myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures.
What are the alternative names for Myxoid Liposarcoma?
  • Myxoid liposarcoma
  • MRCLS
  • Myxoid/round cell liposarcoma
  • Myxoliposarcoma
Who are the top Myxoid Liposarcoma Local Doctors?
Joseph Morris
Experienced in Myxoid Liposarcoma
Dr. Joseph Morris
General Surgery
Experienced in Myxoid Liposarcoma
Dr. Joseph Morris
General Surgery

MercyOne Siouxland Medical Center

801 Fifth Street, 
Sioux City, IA 
 (46.6 mi)
712-279-2010
Languages Spoken:
English
See accepted insurances

Joseph Morris is a General Surgeon in Sioux City, Iowa. Dr. Morris and is rated as an Experienced provider by MediFind in the treatment of Myxoid Liposarcoma. His top areas of expertise are Hernia, Retroperitoneal Inflammation, Familial Colorectal Cancer, Lymphadenectomy, and Hernia Surgery.

Advanced in Myxoid Liposarcoma
Dr. Lisa M. Chaiken
Radiation Oncology
Advanced in Myxoid Liposarcoma
Dr. Lisa M. Chaiken
Radiation Oncology

Siouxland Regional Cancer Center

230 Nebraska St, June E Nylen Cancer Center, 
Sioux City, IA 
 (46.8 mi)
712-252-0088
Languages Spoken:
English, American Sign Language, Spanish
See accepted insurances
Accepting New Patients

Lisa Chaiken is a Radiation Oncologist in Sioux City, Iowa. Dr. Chaiken and is rated as an Advanced provider by MediFind in the treatment of Myxoid Liposarcoma. Her top areas of expertise are Breast Cancer, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Gliosarcoma. Dr. Chaiken is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Myxoid Liposarcoma
Dr. Corey P. Rothrock
Orthopedics
Advanced in Myxoid Liposarcoma
Dr. Corey P. Rothrock
Orthopedics

Orthopedic Institute PC

1202 21st Ave, 
Rock Valley, IA 
 (48.5 mi)
605-331-5890
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Rothrock is an Orthopedics provider in Rock Valley, Iowa. Dr. Rothrock and is rated as an Advanced provider by MediFind in the treatment of Myxoid Liposarcoma. His top areas of expertise are Osteoarthritis, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, Hip Replacement, and Knee Replacement. Dr. Rothrock is currently accepting new patients.

View All Doctors
What are the latest Myxoid Liposarcoma Clinical Trials?
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center